Media about us

  • 29 June 2017

    Syndax Locks In To Tumor Escape

    Syndax Locks In To Tumor Escape

    Seeking Alpha

    Syndax (NASDAQ:SNDX) is a $315 million market cap company focused on developing a pipeline of innovative combination therapies for cancer. The company's lead product is Entinostat, which was granted Breakthrough Therapy Designation by FDA for its Phase 2b clinical trial in advanced hormone receptor positive (Estrogen Receptor positive, ER+) breast cancer. The impact of Breakthrough Therapy Designation on biotechnology stocks has been previously described here by Strong Bio and is worth a read. The company has a host of impressive partnerships for its clinical trials, including Merck (NYSE:MRK) for a combinatory non-small cell lung cancer (NSCLC) and melanoma therapy, Genentech/Roche (OTCQX:RHHBY) for triple-negative breast cancer (TNBC), and Pfizer (NYSE:PFE) and Merck in Germany for ovarian cancer.

  • 16 June 2017

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed

    The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

  • 15 June 2017

    OD reports practices success with corneal inlay

    OD reports practices success with corneal inlay

    Jeffrey M. Augustine, OD / Healio

    The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.

  • 13 June 2017

    Pfizer eyes building another plant in Russia

    Pfizer eyes building another plant in Russia

    ThePharmaLetter

    US pharma giant Pfizer (NYSE: PFE) is considering building another manufacturing plant in Russia during the next several years, which is expected to be located in the Tatarstan Republic, one of Russia’s richest and economically developed regions. In addition on May 30, Pfizer officially started building its first Russian plant in the Kaluga Vorsino technopark, which takes place in cooperation with its local partner NovaMedica.

  • 05 June 2017

    Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

    Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

    Dan Stanton / InPharma Technologist

    Pfizer and NovaMedica have broken ground on a manufacturing facility in Kaluga set to supply the Russian market with sterile injectable drugs. The ceremony this week comes five months after global pharma firm Pfizer announced it had completed the transfer of the rights and technologies for the production of over.
  • 05 June 2017

    The three factors crucial to effectiveness in healthcare

    The three factors crucial to effectiveness in healthcare

    SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.

  • 01 June 2017

    Plant to produce Pfizer sterile injectables for Russia gets under way

    Plant to produce Pfizer sterile injectables for Russia gets under way

    Eric Palmer / Fierce Pharma

    Russia's NovaMedica is building a new sterile injectables plant in the Kaluga region where it will produce 30 of Pfizer’s sterile injected generic meds for the local market.

  • 01 June 2017

    Construction of a new pharmaceutical plant started in Vorsino Industrial Park

    Construction of a new pharmaceutical plant started in Vorsino Industrial Park

    GMP News

    On May 30, Vorsino Industrial Park in the Kaluga region hosted an official ceremony to mark the start of construction of an advanced biopharmaceutical production facility owned by NovaMedica LLC (a RUSNANO investment project).

  • 31 May 2017

    Construction of Pfizer-sponsored pharmaceutical factory starts in Russia

    Construction of Pfizer-sponsored pharmaceutical factory starts in Russia

    Construction.ru

    A ground-breaking ceremony of a pharmaceutical factory was held on Tuesday in Vorsino technology park located near the Russian city of Kaluga. American company Pfizer is an investor of the enterprise's building project. The main partner of the project is NovaMedica, a portfolio company of the Russian government-owned company Rusnano engaged in the development of nanotechnology.

  • 29 May 2017

    Russia  USA. The bilateral business interest in investment remains high.

    Russia USA. The bilateral business interest in investment remains high.

    TASS

    In their first talks, Russia’s President Vladimir Putin and the US President Donald Trump noted the importance of restoring full-scale economic partnership, with due account of the fact that in 2016 Russian-American projects started and continued virtually across the entire economy. The numbers include the US investments in Russian export-oriented and import-substituting industries. A number of such projects began in 2016 alone, with Pfizer’s pharmaceutical factory and Novamedica Company in the Kaluga Region among them.

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news